|
1
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chao Y, Wu CY, Wang JP, Lee RC, Lee WP and
Li CP: A randomized controlled trial of gemcitabine plus cisplatin
versus gemcitabine alone in the treatment of metastatic pancreatic
cancer. Cancer Chemother. Pharmacol. 72:637–642. 2013.
|
|
3
|
Vincent A, Herman J, Schulick R, Hruban RH
and Goggins M: Pancreatic cancer. Lancet. 378:607–620. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Moore MJ, Goldstein D, Hamm J, Figer A,
Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, et al:
National Cancer Institute of Canada Clinical Trials Group:
Erlotinib plus gemcitabine compared with gemcitabine alone in
patients with advanced pancreatic cancer: A phase III trial of the
National Cancer Institute of Canada Clinical Trials Group. J Clin
Oncol. 25:1960–1966. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Stathis A and Moore MJ: Advanced
pancreatic carcinoma: Current treatment and future challenges. Nat
Rev Clin Oncol. 7:163–172. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Borad MJ, Reddy SG, Bahary N, Uronis HE,
Sigal D, Cohn AL, Schelman WR, Stephenson J Jr, Chiorean EG, Rosen
PJ, et al: Randomized phase II trial of gemcitabine plus TH-302
versus gemcitabine in patients with advanced pancreatic cancer. J
Clin Oncol. 33:1475–1481. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen CT, Chen YC, Yamaguchi H and Hung MC:
Carglumic acid promotes apoptosis and suppresses cancer cell
proliferation in vitro and in vivo. Am J Cancer Res. 5:3560–3569.
2015.PubMed/NCBI
|
|
8
|
Waxman S and Anderson KC: History of the
development of arsenic derivatives in cancer therapy. Oncologist.
6(Suppl 2): 3–10. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dangleben NL, Skibola CF and Smith MT:
Arsenic immunotoxicity: A review. Environ. Health. 12:732013.
|
|
10
|
Hynes RO and Lander AD: Contact and
adhesive specificities in the associations, migrations, and
targeting of cells and axons. Cell. 68:303–322. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Burridge K: Are stress fibres contractile?
Nature. 294:691–692. 1981. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Humphries JD, Wang P, Streuli C, Geiger B,
Humphries MJ and Ballestrem C: Vinculin controls focal adhesion
formation by direct interactions with talin and actin. J Cell Biol.
179:1043–1057. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Burridge K and Chrzanowska-Wodnicka M:
Focal adhesions, contractility, and signaling. Annu Rev Cell Dev
Biol. 12:463–518. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Henriksen R, Funa K, Wilander E, Bäckström
T, Ridderheim M and Oberg K: Expression and prognostic significance
of platelet-derived growth factor and its receptors in epithelial
ovarian neoplasms. Cancer Res. 53:4550–4554. 1993.PubMed/NCBI
|
|
15
|
Uren A, Merchant MS, Sun CJ, Vitolo MI,
Sun Y, Tsokos M, Illei PB, Ladanyi M, Passaniti A, Mackall C and
Toretsky JA: Beta-platelet-derived growth factor receptor mediates
motility and growth of Ewing's sarcoma cells. Oncogene.
22:2334–2342. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yamauchi T, Adachi S, Yasuda I, Nakashima
M, Kawaguchi J, Nishii Y, Yoshioka T, Okano Y, Hirose Y, Kozawa O
and Moriwaki H: UVC radiation induces downregulation of EGF
receptor via phosphorylation at serine 1,046/1,047 in human
pancreatic cancer cells. Radiat Res. 176:565–574. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Adachi S, Nagao T, Ingolfsson HI, Maxfield
FR, Andersen OS, Kopelovich L and Weinstein IB: The inhibitory
effect of (−)-epigallocatechin gallate on activation of the
epidermal growth factor receptor is associated with altered lipid
order in HT29 colon cancer cells. Cancer Res. 67:6493–6501. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Glienke W, Chow KU, Bauer N and Bergmann
L: Down-regulation of wt1 expression in leukemia cell lines as part
of apoptotic effect in arsenic treatment using two compounds. Leuk
Lymphoma. 47:1629–1638. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nicolis I, Curis E, Deschamps P and
Bénazeth S: Arsenite medicinal use, metabolism, pharmacokinetics
and monitoring in human hair. Biochimie. 91:1260–1267. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gao M, Dong W, Hu M, Yu M, Guo L, Qian L,
Guo N and Song L: GADD45alpha mediates arsenite-induced cell
apoptotic effect in human hepatoma cells via JNKs/AP-1-dependent
pathway. J Cell Biochem. 109:1264–1273. 2010.PubMed/NCBI
|
|
21
|
Oliver FJ, de la Rubia G, Rolli V,
Ruiz-Ruiz MC, de Murcia G and Murcia JM: Importance of
poly(ADP-ribose) polymerase and its cleavage in apoptosis. Lesson
from an uncleavable mutant. J Biol Chem. 273:33533–33539. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sherr CJ: Cancer cell cycles. Science.
274:1672–1677. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Henson ES and Gibson SB: Surviving cell
death through epidermal growth factor (EGF) signal transduction
pathways: Implications for cancer therapy. Cell Signal.
18:2089–2097. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cheng JQ, Lindsley CW, Cheng GZ, Yang H
and Nicosia SV: The Akt/PKB pathway: Molecular target for cancer
drug discovery. Oncogene. 24:7482–7492. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cross DA, Alessi DR, Cohen P, Andjelkovich
M and Hemmings BA: Inhibition of glycogen synthase kinase-3 by
insulin mediated by protein kinase B. Nature. 378:785–789. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sutherland C, Leighton IA and Cohen P:
Inactivation of glycogen synthase kinase-3 beta by phosphorylation:
New kinase connections in insulin and growth-factor signalling.
Biochem J. 296:15–19. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nakashima M, Adachi S, Yasuda I, Yamauchi
T, Kozawa O and Moriwaki H: Rho-kinase regulates negatively the
epidermal growth factor-stimulated colon cancer cell proliferation.
Int J Oncol. 36:585–592. 2010.PubMed/NCBI
|
